Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel

Cardiovascular Therapeutics

Volumn 33, Issue 5, 2015, Pages 264-269

  Gremmel, Thomas ^a   Durstberger, Markus ^a   Eichelberger, Beate ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Calcium channel blockers; Clopidogrel; Flow cytometry

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FELODIPINE; FIBRINOGEN RECEPTOR; LERCANIDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PADGEM PROTEIN; VERAPAMIL; ANTITHROMBOCYTIC AGENT; DIHYDROPYRIDINE DERIVATIVE; SELP PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AGED; ANGIOPLASTY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY STENTING; CREATININE BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; VASCULAR STENT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; PROCEDURES; STENT; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY; ASPIRIN; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG INTERACTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; TICLOPIDINE;

EID: 84941195648     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12138     Document Type: Article

References (34)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
2. Cattaneo M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 2006;27:1010-1012.
3. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the invitro response/non response to clopidogrel. Thromb Haemost 2011;106:211-218.
4. Mega JL, Close SL, Wiviott SD, etal. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
5. Simon T, Verstuyft C, Mary-Krause M, etal. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
6. Gremmel T, Kopp CW, Moertl D, etal. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thromb Res 2012;129:616-622.
7. Gremmel T, Kopp CW, Seidinger D, etal. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int J Cardiol 2013;166:126-131.
8. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010;8:37-42.
9. Erlinge D, Varenhorst C, Braun OO, etal. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added exvivo. J Am Coll Cardiol 2008;52:1968-1977.
10. Bonello-Palot N, Armero S, Paganelli F, etal. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:1511-1515.
11. Angiolillo DJ, Bernardo E, Capodanno D, etal. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010;55:1139-1146.
12. Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, Panzer S. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant 2013;28:2116-2122.
13. Lau WC, Waskell LA, Watkins PB, etal. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-37.
14. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-189.
15. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-2509.
16. Tantry US, Bonello L, Aradi D, etal. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-2273.
17. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1, 4-dihydropyridine calcium antagonists: prediction of invivo drug-drug interactions. Eur J Clin Pharmacol 2000;55:843-852.
18. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991;34:1838-1844.
19. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-1563.
20. Harmsze AM, Robijns K, van Werkum JW, etal. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103:920-925.
21. Sarafoff N, Neumann L, Morath T, etal. Lackof impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011;161:605-610.
22. Gremmel T, Koppensteiner R, Kaider A, Eichelberger B, Mannhalter C, Panzer S. Impact of variables of the P-selectin - P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thromb Haemost 2014;113:806-812.
23. Gremmel T, Eslam RB, Koppensteiner R, Lang IM, Panzer S. Prasugrel reduces agonists'inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc Ther 2013;31:e40-e45.
24. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-315.
25. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996;87:4925-4936.
26. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of invivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
27. Furman MI, Barnard MR, Krueger LA, etal. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. JAm Coll Cardiol 2001;38:1002-1006.
28. Furman MI, Benoit SE, Barnard MR, etal. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
29. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985;260:11107-11114.
30. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 2014;111:474-482.
31. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011;128:352-357.
32. Harmsze AM, van Werkum JW, Souverein PC, etal. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 2011;9:1892-1901.
33. Ojeifo O, Wiviott SD, Antman EM, etal. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv 2013;6:1275-1281.
34. Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, Berger PB. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovas Interv 2012;5:77-81.